warfarin genotyping | GenomeWeb

warfarin genotyping

Operating since the beginning of the year in a pilot mode, the company officially launched its comprehensive PGx testing service last week.

A study has demonstrated why dosing algorithms for warfarin have performed poorly in patients with African ancestry, especially in recent randomized clinical trials.

A genome-wide association study by researchers at several US and international institutions has found a novel variant — rs12777823 — that explains some of the variability in warfarin metabolism in African-American individuals and could potentially improve the effectiveness of pha

Nanosphere has raised $26.9 million in a public offering that it expects will see it through the regulatory approval of its infectious disease test pipeline and support additional commercial development to bring the firm to the break-even point.

The eventual goal of the partnership would be to port the validated assay onto Rheonix's fully automated, modular molecular testing platform, which is still under development but may reduce the complexity and cost of warfarin sensitivity testing.

The investment firm lowered revenue estimates and the share-price target for Nanosphere following the FDA's denial of the company's Plavix metabolism test.

Pharmigene now has the global licensing rights to VKORC1-1639 SNP-related patents and application from the University of Washington and Academia Sinica.

PGXL will use AutoGenomics' Infiniti analyzer for various personalized medicine applications. Specifically, PGXL plans to use AutoGenomics' FDA-cleared Infiniti warfarin assay and CYP450 2C19 assay.

While past studies that have attempted to gauge the clinical utility of warfarin PGx testing have been hampered by slow test turnaround times, Iverson is promising to provide genetic test results within 24 hours.

Pages

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.